Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yet more news from MGC today via RNS on the progress of CimetrA. I'm expecting the market to wake up to what is happening soon with MGC. The initial trial results are out in the next few weeks....
* MGC Pharma has received Study approvals and an Import Permit from the South African Health Products Regulatory Authority for MGC Pharma's Phase IIb CimetrAâ„¢ dose finding study on patients diagnosed with COVID-19.
CEO: "Clinical trials to date have demonstrated the efficacy of CimetrAâ„¢ against COVID-19, so it is crucial that we are able to complete the dosage trials in Israel and now South Africa as quickly as possible so we can move to the next stage of the clinical pipeline and treat those suffering from the effects of the cytokine storm and "Long COVID" more effectively."
* Recent studies of CimetrAâ„¢ have indicated the mechanism of the drug could be effective in treating other conditions where a primary factor is inflammation. These include autoimmune diseases Irritable Bowel Disease, Rheumatoid arthritis, Influenza, and dermatological diseases, amongst others.
* The establishment of the South African trial site will help to accelerate completion of the ongoing study, and the collection of data necessary for the submission of CimetrAâ„¢ with regulators internationally, which the Company views as a priority, particularly at a time when cases of COVID-19 are once again on the rise.
* The Trial will incorporate key parameters, which include determining the most effective dosage of the treatment, a full safety and Pharmacovigilance profile, and an extensive Pharmacokinetic profile of CimetrAâ„¢ to outline the registration and administrative process for approval for sale and use. The Trial will further examine the anti-inflammatory and immune-modulatory effects of CimetrAâ„¢ through Cytokine level monitoring. The study to be undertaken in South Africa is an extension of the dosing study currently underway in Israel (See announcement 2 November 2021), with interim analysis results due in the coming weeks.
Exciting times for MGC investors in the coming weeks.
Good luck, Brighty
Great post Brighty. If only he'd just spent 5-10 mins Googling those illnesses before he typed out that negative post eh?
For some additional context these are not small numbers for MGC to be targeting with CimetrATM:
* Rheumatoid arthritis affects about 1.3 million adults in the USA. Worldwide, it is estimated to occur in up to 1 percent of the population. i.e. it is a massive market to be targetting.
* Inflammatory bowel disease (including Crohn's disease and ulcerative colitis) affect five million people worldwide.
* Asthma affects more than 300 million people worldwide. i.e. a huge market.
* Chronic obstructive pulmonary disease (COPD) accounted for 390+ million cases among people aged 30–79 years in 2019 and we know that that number will have drastically increased with Covid. i.e. an enormous market.
I wouldn't say that these are "niche" markets as per one of the earlier posts today. This is an expansive market for MGC to be tapping in to. When investors cotton on to what MGC is up to the share price will start to move. It's a waiting game but an investment case that looks more and more promising with each RNS. Lets hope a big pharma doesn't snap up MGC too early as the share price could be many times higher in due course.
Good luck, Brighty
Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented : "We have long had confidence in CimetrA, and this latest study on its mechanism of action highlights even more potential applications for the product. This is a big leap forward, with more conditions potentially being able to be treated treatable with the drug.
"Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirms the findings of previous studies
"We are making plans for the next phase of its clinical journey and will keep everyone updated. "
More encouraging news from MGC today that CimetrATM might have a wider-ranging application as an anti-inflammatory treatment, beyond the treatment of the symptoms of COVID-19.
The RNS makes for very interesting reading regarding the scope CimetrATM could have for the pharma sector and patients including rheumatoid arthritis, Inflammatory bowel disease, asthma, psoriasis and chronic obstructive pulmonary disease. This has just added considerable value to the business in the medium to long term.
Roby Zomer's quote says it all: "We have long had confidence in CimetrA, and this latest study on its mechanism of action highlights even more potential applications for the product. This is a big leap forward, with more conditions potentially being able to be treated treatable with the drug.
"Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirms the findings of previous studies".
At some stage pretty soon a major pharma is surely going to look at buying this business. Today is another good news day from MGC. Looking good moving forward. Good luck, Brighty